Literature DB >> 2857362

Diversity of clinical spectrum of HTLV-III infection.

S L Valle, C Saxinger, A Ranki, J Antonen, J Suni, J Lähdevirta, K Krohn.   

Abstract

In a prospective follow-up volunteer study lasting 4 to 16 months, 17 of 200 homosexual men living in Finland had antibodies to human T-lymphotrophic virus type III (HTLV-III). 1 man who initially had a low titre of HTLV-III antibodies became seronegative within 6 months without any symptoms developing, and a seronegative man became seropositive. 14 men had high titres of HTLV-III antibodies when they first joined the study and during the study titres rose in all other HTLV-III-positive men except those with AIDS. Initially 9 men were symptom-free, 3 had lymphadenopathy syndrome (LAS), 3 had AIDS-related complex (ARC), and 2 had AIDS. During follow-up LAS developed in 3 symptom-free HTLV-III positive men but none of those with LAS or ARC progressed to AIDS. Most HTLV-III-positive men, including those who were otherwise symptom-free, had mucocutaneous lesions generally associated with immune deficiency. Regardless of the symptoms, those with increasing HTLV-III antibody titres showed lowered T helper/T suppressor ratios, decreased numbers of T helper cells, and/or diminished responses to tuberculin antigen (PPD). These results suggest that the clinical spectrum of HTLV-III infection ranges from transient infection through chronic provirus state, asymptomatic virus producer state, LAS or ARC, and rarely full-blown AIDS. Cofactors probably determine the final outcome of infection in the individual.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Behavior; Developed Countries; Diseases; Europe; Finland; Hiv Infections; Homosexuals; Northern Europe; Prospective Studies; Scandinavia; Sex Behavior; Viral Diseases

Mesh:

Substances:

Year:  1985        PMID: 2857362     DOI: 10.1016/s0140-6736(85)91080-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

1.  Impaired cell mediated immunity in haemophilia in the absence of infection with human immunodeficiency virus.

Authors:  R Madhok; A Gracie; G D Lowe; A Burnett; K Froebel; E Follett; C D Forbes
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-18

2.  AIDS: no time for apathy.

Authors:  W Greaves
Journal:  J Natl Med Assoc       Date:  1986-02       Impact factor: 1.798

3.  Progressive cellular immune impairment leading to development of AIDS: two-year prospective study of HIV infection in drug addicts.

Authors:  E Fernandez-Cruz; A M Fernandez; C Gutierrez; M Garcia-Montes; M T de la Morena; J Rodriguez-Villanueva; N Longo; J M Zabay
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

Review 4.  AIDS: a problem for intensive care.

Authors:  R A Banks; K J Lindley; A L Pozniak
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

Review 5.  Infectious diseases in Africa.

Authors:  E A Ayoola
Journal:  Infection       Date:  1987 May-Jun       Impact factor: 3.553

6.  Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.

Authors:  A Ranki; S H Weiss; S L Valle; J Antonen; K J Krohn
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

7.  The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls.

Authors:  W J Boyko; M T Schechter; K J Craib; P Constance; R Nitz; S Fay; A McLeod; M O'Shaughnessy
Journal:  CMAJ       Date:  1986-10-15       Impact factor: 8.262

8.  [Follow-up in HIV-infected homosexual males with lymphadenopathy syndrome].

Authors:  T Harrer; K Messing; U Bienzle; E Meyer; J Giedl; J R Kalden
Journal:  Klin Wochenschr       Date:  1987-09-15

9.  The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells.

Authors:  M T Schechter; W J Boyko; E Jeffries; B Willoughby; R Nitz; P Constance; M Weaver; B Wiggs; M O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-08-15       Impact factor: 8.262

10.  Interleukin 2 production in HTLV-III/LAV infection: evidence of defective antigen-induced, but normal mitogen-induced IL-2 production.

Authors:  J Antonen; K Krohn
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.